Stevanato Group S.p.A. (STVN) Stock: Price, Forecast & Analyst Target
Stevanato Group S.p.A. (STVN) — MoonshotScore 80/100 (Exceptional band), calculated Oct 5, 2026. Price $20.05 (-0.74%), as of the Oct 5, 2026 trading session; market cap $5.47B. Expected results Nov 5, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Stevanato Group S.p.A. · STVN · NYSE · Healthcare · Medical - Instruments & Supplies
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Stevanato Group S.p.A. (STVN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Solid; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $339M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z 4.18 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 81 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 80 | Strong |
The score was 80 in the stored Oct 4, 2026 snapshot and remains 80 in the current publication computed Oct 5, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $20.05 | |
| Change on the day | -0.74% | |
| 52-week range | $12.89–$27.99 | |
| Market capitalisation | $5.47B | |
| Price / earnings (trailing) | 37.66 | |
| Shares traded on the day | 652.6K | |
| Beta (volatility vs the S&P 500) | 0.75 | |
| Dividends per share (last 12 months) | $0.06 | |
| Dividend yield (last 12 months) | 0.31% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
The build-out for our first device program remains on track, and we continue to expect commercial production to begin later this year.
Franco Stevanato · Statement from
Our approach is always to maintain certain free capacity in order to enhance our plants to have the flexibility also to do the sampling and the validation for the future program that we're going to start to host in the next year to come.
Franco Stevanato · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Stevanato Group S.p.A. (STVN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the STVN film — every key number, told as a short cinematic story
~2 min · open the film
What is Stevanato Group S.p.A. (STVN), and what does it report?
Short answer · as of
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Stevanato Group S.p.A. (STVN) is listed on NYSE. Healthcare / Medical Instruments & Supplies SEC filing business address: Piombino Dese (PD) VIA Molinella, 17, Padua, 35017. It employs 6,010 people and is led by Franco Stevanato. In Q2 FY2026 it reported revenue of $339M and net income of $26M. The market values it at $5.47B.
What do the latest results show for Stevanato Group S.p.A. (STVN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $339M. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $344.90M Aug 4, 2026
- Latest report · revenue estimate
- $340.58M Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $344.90M | $340.58M | $0.1600 | $0.1448 |
| May 7, 2026 | $316.11M | $310.47M | $0.1300 | $0.1200 |
| Mar 4, 2026 | $406.97M | $391.27M | $0.2100 | $0.2000 |
| Nov 6, 2025 | $355.08M | $385.49M | $0.1600 | $0.1400 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $339M | $26M | $0.09 (diluted) |
| Q1 FY2026 | $307M | $31M | $0.12 (diluted) |
| Q4 FY2025 | $385M | $53M | $0.19 (diluted) |
| Q3 FY2025 | $340M | $40M | $0.15 (diluted) |
What are the financial strengths and risks for Stevanato Group S.p.A. (STVN)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 4.18 · Piotroski F 6. Trailing ratios: ROE 8.9% · ROA 5.1% · current ratio 1.61 · earnings yield 2.6% · free-cash-flow yield -0.5%.
What should you watch next at Stevanato Group S.p.A. (STVN)?
Short answer · as of
The next earnings report is expected on Nov 5, 2026. Current published price targets run low $17.50 · high $33.00 · consensus $25.58 · median $26.00 against a quoted price of $20.05 (as of Oct 5, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
The build-out for our first device program remains on track, and we continue to expect commercial production to begin later this year.
Franco Stevanato ·
Our approach is always to maintain certain free capacity in order to enhance our plants to have the flexibility also to do the sampling and the validation for the future program that we're going to start to host in the next year to come.
Franco Stevanato ·
And as a reminder, Paul, Marco speaking, we plan to fully ramp up Fishers by the end of 2028.
Marco Dal Lago ·
So we expect in Q3 and Q4 further margin expansion in our BDS segment driven by the growth in Fishers and Latina and driven by the fact that we expect a stronger second half of the year, so a better leverage on our fixed expenses, again mainly driven by Fishers and Latina.
Marco Dal Lago ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
Checked against the records this page reads, on the dates shown above.
How does Stevanato Group S.p.A. compare with its peers?
Short answer
Stevanato Group S.p.A.'s score ranks 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Stevanato is a consolidated supplier of critical pharma manufacturing infrastructure, a position earned through manufacturing excellence and regulatory relationships. The company is not a low-cost commodity manufacturer—it competes on quality, compliance, and integrated solutions (vials plus delivery systems plus processing equipment from a single vendor). This integrated model is different from pure vial manufacturers or pure equipment builders.
Compared to peer equipment makers (Bausch + Lomb parent Bausch Health competitors), Stevanato is more exposed to consumable demand cycles. Compared to pure vial suppliers, Stevanato has scale advantages and integrated offerings. Compared to contract manufacturers, Stevanato is upstream in the supply chain, insulated from formulation risk. The real peer set is large-cap pharma suppliers like Sartorius or Getinge, all facing shared cycles around pharma capital spending and biotech activity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $56.37 Oct 5, 2026 | $2.87B | 97 5-pillar Oct 5, 2026 | |
| $104.68 Oct 5, 2026 | $4.76B | 87 5-pillar Oct 5, 2026 | |
| $87.14 Oct 5, 2026 | $5.20B | 85 5-pillar Oct 5, 2026 | |
| $62.00 Oct 5, 2026 | $12.2B | 83 5-pillar Oct 5, 2026 | |
| $189.50 Oct 5, 2026 | $10.7B | 82 5-pillar Oct 5, 2026 | |
| Stevanato Group S.p.A. (STVN) — this page | $20.05 | $5.47B | 80 |
| $120.61 Oct 5, 2026 | $7.59B | 76 5-pillar Oct 5, 2026 | |
| $161.40 Oct 5, 2026 | $4.03B | 66 5-pillar Oct 5, 2026 | |
| $26.65 Oct 5, 2026 | $3.27B | 63 5-pillar Oct 5, 2026 | |
| $15.81 Oct 5, 2026 | $10.6B | 56 5-pillar Oct 5, 2026 | |
| $125.24 Oct 5, 2026 | $5.49B | 55 5-pillar Oct 5, 2026 | |
| $177.08 Oct 5, 2026 | $9.11B | 33 5-pillar Oct 5, 2026 | |
| $17.17 Oct 5, 2026 | $6.13B | 33 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $17.50 – $33.00
- Consensus target
- $25.58
- Median target
- $26.00
Consensus record · Captured .
Measured against a quoted price of $20.05 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 28, 2026
- Transactions
- 25
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 8
- Other transactions
- 17
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 16.4% Period end Jun 30, 2026
- Previous quarter · ownership
- 16.3% Prior to period end Jun 30, 2026
- Reporting holders
- 127 Period end Jun 30, 2026
- Previous quarter · holders
- 136 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Conestoga Capital Advisors, LLC | 7,007,613 |
| Neuberger Berman Group LLC | 5,622,269 |
| Timessquare Capital Management, LLC | 3,474,641 |
| Van Berkom & Associates INC. | 2,969,220 |
| Artisan Partners Limited Partnership | 2,601,598 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Stevanato Group S.p.A. (STVN)?
- UBS Adjusts Price Target on Stevanato Group to $23 From $28, Keeps Neutral Rating
- Stevanato Group to Participate in Two Upcoming Investor Conferences
- Stevanato Group (STVN) Trades A Subsidiary For Margin Gains And Growth
- A Look at Stevanato Group SpA (STVN) After 3.4% Decline -- GF Value $25.98 vs Price $20.71
What Investors Ask About Stevanato Group S.p.A. (STVN) — Healthcare
These answers are editorial: 1 of these 9 answers is drawn from the STVN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for STVN?
STVN carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Stevanato Group S.p.A. provides integrated solutions for the pharmaceutical and healthcare industries.
Is STVN a good stock to buy?
Stock Expert AI does not rate STVN buy, sell or hold. Stevanato Group S.p.A. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the STVN stock price today?
The last price recorded on this page for Stevanato Group S.p.A. (STVN) is $20.05, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the STVN price target?
The analyst consensus price target for Stevanato Group S.p.A. (STVN) is $25.58 (range $17.50 to $33.00, median $26.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for STVN?
Stevanato Group S.p.A. faces several risks inherent to the medical instruments and supplies industry. Economic downturns and reduced healthcare spending could negatively impact demand for its products and services.
What are the key factors to evaluate for STVN?
Stevanato Group S.p.A. (STVN) holds a MoonshotScore in the high range. P/E: 37.66x. Analysts target $25.58 (+28%). By establishing a presence in these markets, Stevanato Group can tap into new customer bases and diversify its revenue streams. Not financial advice.
How frequently does STVN data refresh on this page?
STVN's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven STVN's recent stock price performance?
Stevanato Group S.p.A. (STVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in the pharmaceutical and healthcare industries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STVN overvalued or undervalued right now?
Stevanato Group S.p.A. (STVN) trades at 37.66x earnings. Analysts target $25.58 (+28%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (58 figures)
The 58 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Franco Stevanato (Aug 4, 2026): The build-out for our first device program remains on track, and we continue to expect commercial production to begin later this year. Franco Stevanato (Aug 4, 2026): Our approach is always to maintain certain free capacity in order to enhance our plants to have the flexibility also to do the sampling and the validation for the future program that we're going to start to host in the next year to come. Marco Dal Lago (Aug 4, 2026): And as a reminder, Paul, Marco speaking, we plan to fully ramp up Fishers by the end of 2028. Marco Dal Lago (Aug 4, 2026): So we expect in Q3 and Q4 further margin expansion in our BDS segment driven by the growth in Fishers and Latina and driven by the fact that we expect a stronger second half of the year, so a better leverage on our fixed expenses, again mainly driven by Fishers and Latina. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Piombino Dese (PD) VIA Molinella, 17, Padua, 35017 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Via Molinella, 17, Piombino Dese, PD, 35017, IT". |
FMP — 46 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $20.05 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:53.233Z. | |
px.change | Change on the day | -0.74% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.47B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:03.000Z. Captured from FMP at 2026-10-05T21:44:52.202Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 5, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.15 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $339M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $12.89–$27.99 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 37.66 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 652.6K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.75 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Instruments & Supplies | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 3841 — Surgical & Medical Instruments & Apparatus. | |
id.employees | Employees | 6,010 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Franco Stevanato | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | $26M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $344.90M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $340.58M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | $0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | $0.1448 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $316.11M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $310.47M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $0.1300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | $0.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.revenue_actual | Revenue · reported — report date 2026-03-04 | $406.97M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.revenue_estimated | Revenue · estimate — report date 2026-03-04 | $391.27M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.eps_actual | EPS · reported — report date 2026-03-04 | $0.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.eps_estimated | EPS · estimate — report date 2026-03-04 | $0.2000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_actual | Revenue · reported — report date 2025-11-06 | $355.08M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_estimated | Revenue · estimate — report date 2025-11-06 | $385.49M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_actual | EPS · reported — report date 2025-11-06 | $0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_estimated | EPS · estimate — report date 2025-11-06 | $0.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $17.50 · high $33.00 · consensus $25.58 · median $26.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $17.50 – $33.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $25.58 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $26.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 25 transactions · 0 purchases, 8 sales, 17 other transactions · 9 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 28, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 16.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 16.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 127 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 136 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Conestoga Capital Advisors, LLC — shares in provider snapshot | 7,007,613 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Neuberger Berman Group LLC — shares in provider snapshot | 5,622,269 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Timessquare Capital Management, LLC — shares in provider snapshot | 3,474,641 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Van Berkom & Associates INC. — shares in provider snapshot | 2,969,220 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Artisan Partners Limited Partnership — shares in provider snapshot | 2,601,598 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-30 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 4.18 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 8.9% · ROA 5.1% · current ratio 1.61 · earnings yield 2.6% · free-cash-flow yield -0.5% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.06 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.31% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($344.90M) with the recorded estimate ($340.58M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1600) with the recorded estimate ($0.1448) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 80 of 100 · Exceptional · pillars 77 / 69 / 56 / 91 / 74 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 80 (stored snapshot Oct 4, 2026) → 80 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-03-04.revenue_actual,earn.history.depth.2026-03-04.revenue_estimated,earn.history.depth.2026-03-04.eps_actual,earn.history.depth.2026-03-04.eps_estimated,earn.history.depth.2025-11-06.revenue_actual,earn.history.depth.2025-11-06.revenue_estimated,earn.history.depth.2025-11-06.eps_actual,earn.history.depth.2025-11-06.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Trailing twelve-month ratio set | Quick ratio: 1.08; Current ratio: 1.61; Debt to equity: 0.29; Net margin: 11%; Gross margin: 29.2%; Operating margin: 16.1%; Return on assets: 5.1%; Return on equity: 8.9% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.